Association of HMGB1 gene polymorphism and drug treatment in patient with essential hypertension

Abstract

Abstract: AIM: To explore the effect of HMGB1 gene polymorphism on drug treatment in patient with essential hypertension, to raise cure rate of hypertension patients by reasonable cure. METHODS: A cross-sectional study of 780 patients with hypertension that were recruited by taking compound reserpine, Zhen Ju Jiang Ya Tablet and Jiang Ya Tablet, was conducted and three tagging single nucleotide polymorphisms (tagSNPs) of HMGB1 gene (rs1045411, rs1412125, rs2249825) were selected by linkage disequilibrium (LD) analysis and functional prediction. A quantitative trait analysis was performed for evaluating the relation between HMGB1 genetic variation and blood pressure by taking different antihypertensives drugs.RESULTS:In hypertensive taking compound reserpine, after adjusting the confounding factors, diastolic blood pressure (DBP) linearly decreased with the variation (T>C) of rs1412125 (P=0.040). In female hypertensive taking Zhen Ju Jiang Ya Tablet,after adjusting the covariant, systolic blood pressure(SBP) significantly decreased with the variation(G>A) of rs1045411 and the variation (C>G) of rs2249825 respectively (P=0.044 and 0.043). In age≥55 hypertensive taking Jiang Ya Tablet, different genotypes were significantly different after adjusting the covariant(P=0.048). CONCLUSION: HMGB1 gene might affect the antihypertensive effect of compound reserpine, Zhen Ju Jiang Ya Tablet and Jiang Ya Tablet.

Key words: HMGB1 gene, gene polymorphism, essential hypertension, hypotensive drugs, therapeutic effect

CLC Number:

GUO Dao-xia, CHEN Yan-chun, WANG Lin-hong, LU Wei, SHEN Chong, YANG Song, ZHAO Xiang-hai, JIN Yue-long, YAO Ying-shui. Association of HMGB1 gene polymorphism and drug treatment in patient with essential hypertension[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(7): 766-771.

References

[1] Gu D, Reynolds K, Wu X, et al.Prevalence, awareness, treatment, and control of hypertension in china[J]. Hypertension,2002,40(6):920-927.
[2] Read CM, Cary PD, Crane-Robinson C, et al.Solution structure of a DNA-binding domain from HMG1[J]. Nucleic Acids Res,1993,21(5):3427-3436.
[3] Javaherian K, Liu JF, Wang JC.Nonhistone proteins HMG1 and HMG2 change the DNA helical structure[J]. Science, 1978,199(4335):1345-1346.
[4] Wang H, Bloom O, Zhang M, et al.HMG-1 as a late mediator of endotoxin lethality in mice[J]. Science,1999,285(5425):248-251.
[5] Lu B, Nakamura T, Inouye K, et al.Novel role of PKR in inflammasome activation and HMGB1 release[J].Nature, 2012,488(7413):670-674.
[6] Park JS, Svetkauskaite D, He Q, et al.Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein[J].J Biol Chem ,2004,279(9):7370-7377.
[7] Hori O, Brett J, Slattery T, et al.The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system[J]. J Biol Chem,1995,270(43):25752-25761.
[8] Yan XX, Lu L, Peng WH, et al.Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients[J].Atherosclerosis,2009,205(2):544-548.
[9] Yang D, Chen Q, Yang H, et al.High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin[J].J Leukoc Biol ,2007,81(1):59-66.
[10] Hreggvidsdottir HS, Lundberg AM, Aveberger AC, et al.High mobility group box protein 1 (HMGB1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor[J].Mol Med,2012,18:224-230.
[11] de Souza AW, Westra J, Limburg PC, et al. HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis[J].Autoimmun Rev ,2012,11(12):909-917.
[12] Xu H, Yao Y, Su Z, et al.Endogenous HMGB1 contributes to ischemia-reperfusion-induced myocardial apoptosis by potentiating the effect of TNF-α/JNK[J].Am J Physiol Heart Circ Physiol, 2011,300(3):H913-921.
[13] Andrassy M, Volz HC, Igwe JC, et al.High-mobility group box-1 in ischemia-reperfusion injury of the heart[J].Circulation, 2008,117(25):3216-3226.
[14] Kitahara T, Takeishi Y, Harada M, et al.High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice[J]. Cardiovasc Res,2008,80(1):40-46.
[15] Limana F, Germani A, Zacheo A, et al.Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation[J]. Circ Res, 2005,97(8):e73-83.
[16] Takahashi K, Fukushima S, Yamahara K, et al.Modulated inflammation by injection of high-mobility group box 1 recovers post-infarction chronically failing heart[J].Circulation, 2008,118(14 Suppl ):S106-114.
[17] Limana F, Esposito G, D'Arcangelo D, et al. HMGB1 attenuates cardiac remodelling in the failing heart via enhanced cardiac regeneration and miR-206-mediated inhibition of TIMP-3[J].PLoS One,2011,6(6):e19845.
[18] Bauer EM, Shapiro R, Zheng H, et al.High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4[J].Mol Med,2012,18:1509-1518.
[19] 陈宇, 祝善俊. 高血压药物的药物基因组研究进展[J].心血管病学进展,2006,27(2):230-232.
[20] 李刚强, 阎伟, 巢胜吾, 等. 原发性高血压患者中血管紧张素Ⅱ2型受体基因A1675G多态性与缬沙坦降压疗效的相关性研究[J].中国临床药理学与治疗学,2012,17(2):185-188.